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ABSTRACT:
In early stages of metastasis malignant cells must acquire phenotypic changes to 
enhance their migratory behavior and their ability to breach the matrix surrounding 
tumors and blood vessel walls. Epigenetic regulation of gene expression allows 
the acquisition of these features that, once tumoral cells have escape from the 
primary tumor, can be reverted. Here we report that the expression of the Polycomb 
epigenetic repressor Ring1B is enhanced in tumoral cells that invade the stroma in 
human ductal breast carcinoma and its expression is coincident with that of Fak in 
these tumors. Ring1B knockdown in breast cancer cell lines revealed that Ring1B is 
required to sustain Fak expression in basal conditions as well as in Tgfβ-treated cells. 
Functionally, endogenous Ring1B is required for cell migration and invasion in vitro 
and for in vivo invasion of the mammary fat pad by tumoral cells. Finally we identify 
p63 as a target of Ring1B to regulate Fak expression: Ring1B depletion results in 
enhanced p63 expression, which in turns represses Fak expression. Importantly, Fak 
downregulation upon Ring1B depletion is dependent on p63 expression. Our findings 
provide new insights in the biology of the breast carcinoma and open new avenues 
for breast cancer prognosis and therapy.
INTRODUCTION 
Breast cancer is a heterogeneous disease, ranging 
from premalignant hyperplasia to invasive and metastatic 
carcinomas. Metastatic dissemination of tumoral cells 
contributes to more than 90% of mortality in breast 
cancer and is the second leading cause of cancer related 
mortalities in women.  In addition to well characterized 
genetic alterations, breast cancer also appears to exhibit 
specific epigenetic modifications [1]. Epigenetic changes 
in the tumoral cells may promote metastasis by selecting 
those cells with enhanced invasiveness and colonizing 
faculties. Indeed, aberrant expression of a number of 
histone modifying enzymes has been correlated with 
breast cancer prognosis [2-5]. 
The Polycomb family of epigenetic proteins 
comprises transcriptional repressors that are often 
misregulated in several types of human cancer, impinging 
on tumor proliferation, immortalization and metastasis. 
In mammals, two main biochemically and functionally 
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distinct Polycomb core complexes have been identified: 
Polycomb repressive complex 2 and 1 (PRC2 and PRC1, 
respectively) [6]. The PRC2 core complex contains the 
histone methyltransferase Ezh2, which catalyzes the 
trimethylation of histone H3 at lysine 27 (H3K27me3), 
a transcriptionally repressive histone mark [7]. The 
H3K27me3 is the docking site for proteins of the PRC1 
complex harboring a chromobox domain, although 
functional PRC1 complexes can also be recruited in the 
absence of PRC2 [8,9]. The catalytic activity of PRC1 
relies on Ring1B, which acts as ubiquitin E3 ligase 
towards histone H2A at lysine 119 [10]. Proteomic 
profiling of the family of PRC1 complexes revealed that, 
in mammals, distinct and heterogeneous PRC1 complexes 
that exert specific functions could be formed [11]. All 
PRC1 complexes contain Ring1B, that forms functionally 
different PRC1 complex through its interaction with 
different combinations of the Drosophila PSC orthologs 
(Mel-18, Bmi1, or NSPC1), PH orthologs (Phc1, Phc2, 
or Phc3) and PC orthologs (Cbx2, Cbx4, Cbx6, Cbx7, or 
Cbx8) [12]. PRC1 functional complexity is highlighted by 
the fact that Ring1B knockout mice are early embryonic 
lethal, whereas Mel-18, Cbx2, or Bmi1 mutant mice are 
born but display distinct homeotic phenotypes [13-16]. 
Up to now, the role of Polycomb in breast cancer 
has been mainly addressed to investigate the expression 
or the function of two Polycomb proteins, EZH2 and 
BMI1 (PRC2 and PRC1 complexes, respectively). Indeed, 
overexpression of EZH2 was shown to correlate with 
breast cancer aggressiveness and poor patient prognosis 
[2,4] and the PRC2 complex is up-regulated in breast 
cancer lymph node metastasis compared to primary 
tumors [17]. On the contrary, EZH2 knockdown in highly 
aggressive MDA-MB-231 cells decreased the metastatic 
burden and reduced the invasiveness of breast cancer cells 
at the metastatic site [18]. BMI1 overexpression often 
correlates with poorer prognosis and treatment failure 
in different epithelial tumors [19-22]. However, the 
relationship between BMI1 expression and prognosis in 
breast cancer remains controversial: although it has been 
reported that BMI1 is overexpressed in advanced stages 
of breast cancer [23], BMI1 expression has been linked to 
good outcome in breast cancer [4].
Our group has previously demonstrated that Ring1B 
expression is significantly and persistently up-regulated 
in high-grade pancreatic intraepithelial neoplasia and in 
pancreatic ductal adenocarcinoma, but not in early stages 
of the neoplasia or in precursor lesions for pancreatic 
cancer [24]. Therefore, we postulated that Ring1B could 
be required for essential properties of the tumoral cell 
in invasive stages of epithelial tumors. In this study we 
sought to explore the role of Ring1B in breast cancer. We 
here describe that Ring1B displays a coincident expression 
with Fak in human invasive ductal breast carcinomas and 
ectopic Ring1B is able to enhance Fak expression and cell 
migration in vitro. Accordingly, endogenous Ring1B is 
required for proper Fak expression in mammary epithelial 
tumor cells in vitro. Functionally, Ring1B expression is 
required for in vitro cell migration and invasion and for 
in vivo MDA-MB-231 invasion of the mammary stroma 
of the murine orthotopic xenograft host. Finally, in an 
attempt to identify the molecular mechanism underlying 
this phenomenon, we report that maintenance of Fak 
steady state levels relies on p63 repression by endogenous 
Ring1B.  
RESULTS
Ring1B is overexpressed in the invading cells of 
ductal breast carcinoma
We analyzed Ring1B expression by 
immunohistochemistry in ten surgical samples of invasive 
ductal carcinoma (IDC) and in a commercial tissue 
microarray (TMA) consisting of six breast invasive 
ductal carcinoma tissues. Whereas Ring1B is barely 
detectable in the mammary ducts in histologically normal 
regions adjacent to the tumor, carcinoma cells display 
a moderate Ring1B staining signal (0.5 [0-1] and 2 [1-
2.5], respectively; Spearman´s rho correlation coefficient, 
0.854; p<0.000). Interestingly, Ring1B expression reaches 
the maximal intensity of the immunohistochemistry 
staining (value of 3) in those cells invading the surrounding 
fat tissue in six out of the ten surgical IDC samples tested 
(Figure 1A). To better characterize these tumors, we 
performed immunohistochemistry to detect the expression 
of the cytoskeletal calcium-binding protein S100A4, since 
its nuclear, but not cytoplasmic, expression is associated 
with aggressive behavior of different epithelial tumors 
and poor patient outcome [25,26]. Indeed, nuclear 
S100A4 positive staining can be detected in tumoral cells 
invading the stroma (Figure 1B). Immunohistochemistry 
on sequential sections from the same tumor revealed 
that Ring1B expression is enhanced in those regions that 
displayed positive nuclear staining for S100A4 (Figure 
1B), suggesting that Ring1B expression could be linked 
to a poor IDC prognosis. Since PRC1 exhibits a variable 
composition of proteins we also investigated Bmi1, that 
has been found overexpressed in breast cancer, where it is 
associated with a good prognosis [4]. In stark contrast to 
the enhanced expression of Ring1B in the cells invading 
the stroma, Bmi1 expression is maintained, or in many 
instances reduced, in these invading cells when compared 
to the expression in carcinoma cells inside the bulk of 
the tumor (Figure 1B), suggesting a functional difference 
between both PRC1 proteins in ductal breast cancer.
Oncotarget2067www.impactjournals.com/oncotarget
Ring1B is coexpressed with Fak in IDC and is 
able to induce Fak expression
A key protein that integrates signals from growth 
factors and integrins to control cell migration and invasion 
is the non-receptor Focal adhesion kinase (Fak)[27]. Fak 
is required for the transition of premalignant hyperplasias 
to carcinomas and their subsequent metastases and a 
large proportion of primary human breast cancers possess 
elevated Fak expression that is further correlated with 
malignant transformation and poor clinical outcome 
[28,29]. Therefore, we investigated Ring1B and Fak 
expression in serial sections of IDC surgical samples. 
Basal cells of the ducts do not express Ring1B nor Fak, 
whereas luminal cells express both proteins. In addition, 
tumoral cells embed in the stroma display a positive 
staining for both Ring1B and Fak (Figure 2A). In the TMA 
tissues, a moderate to strong immunoreactivity for Fak can 
be detected in four of these tumors (4/6). Interestingly, 
Ring1B is expressed in three of these Fak-positive tumors 
(Figure 2B), whereas two tumors were negative for both 
Fak and Ring1B expression. To better characterize Ring1B 
and Fak relationship, we quantified Fak expression in 
tissue adjacent to the tumor and in tumoral cells of the 
surgical and the TMA samples. Whereas Fak is barely 
detectable in normal ducts, its expression in tumoral 
cells is enhanced (2 [2-3] versus 0 [0-1]). Correlation 
analysis revealed that the expression of Ring1B and Fak 
is associated both in normal adjacent ducts (correlation 
coefficient: 0.600, p<0.039) and in the IDC tumoral 
cells (correlation coefficient: 0.505, p<0.046). Double 
immunohistochemical staining on the same slides showed 
that IDC cells coexpress Ring1B and Fak (Figure 2C), 
further strengthening the link between Ring1B and Fak.
These observations lead us to investigate Ring1B 
ability to induce Fak expression in 293T cells, a cell 
line previously used to study Fak regulation by different 
transcription factors [30,31]. As Figure 3A shows, transient 
transfection of Ring1B results in the upregulation of Fak 
expression. Similar results were achieved when mammary 
epithelial NMuMG cells were transiently transfected with 
a Ring1B expressing vector. In these cells, ectopic Ring1B 
enhances Fak expression (Figure 3A) which localizes at 
focal contacts in the periphery of the cells (Figure 3B). In 
addition, Ring1B overexpressing NMuMG cells display 
enhanced cell migration, as determined by scratch assays 
(Figure 3C).
Figure 1: Ring1B expression in invasive ductal breast 
carcinoma. A. Staining for Ring1B is weak in cells of adjacent 
normal human mammary ducts (picture on the left), medium 
in invasive ductal carcinoma cells (middle) and strong in 
carcinoma cells invading mammary fat (right) within the same 
tumor tissue. Sections were counterstained with Hematoxylin. B. 
Immunohistochemistry analysis of Ring1B, S100A4 and Bmi1 
expression in serial sections of two different invasive ductal 
breast carcinoma samples. Bars, 100 μm.
Figure 2: Ring1B expression is directly associated 
with Fak expression in invasive ductal carcinoma. A. 
Immunohistochemistry analysis of Ring1B and Fak expression in 
serial sections of two invasive ductal breast carcinoma samples. 
On the left, higher magnifications of the fields indicated in the 
right panels. Dashed lines indicate carcinoma cells embedded 
in the tumoral stroma and arrows correspond to luminal cells 
of a duct within tumoral stroma. Observe that Ring1B and 
Fak expression patterns overlapped. Bars, 100 μm. B. Ring1B 
and Fak expression in serial sections of normal adjacent tissue 
(upper left corner) and three invasive ductal breast carcinoma 
tissues in a commercial tissue microarray. Lower panels, higher 
magnification pictures for the tumors shown above. C. Double 
staining analysis of Ring1B (brown) and Fak (pink) in adjacent 
normal mammary ducts and in carcinoma cells. Bars, 100 μm. 
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Endogenous Ring1B sustains steady state Fak 
levels and is required for Tgfβ-induced phenotypic 
changes
To investigate the role of endogenous Ring1B in the 
expression of Fak in breast cancer cells, we downregulated 
Ring1B levels in the MCF7 and MDA-MB-231 cell 
lines by transfecting them with small interfering RNA 
oligos (siRNA). Knockdown efficiency was assessed 
by western blot and qRT-PCR (Figure 4A and Suppl. 
Figure 1, respectively). Since it has been reported that 
Tgfβ can induce Fak expression and activation [32,33], 
we also tested whether endogenous Ring1B is required 
to regulate Fak both in basal and in Tgfβ-treated cells. 
Ring1B depletion leads to drops in the steady state levels 
of Fak protein and mRNA, as revealed by western blot and 
qRT-PCR analysis respectively (Figure 4A). In addition, 
Tgfβ treatment does not restore Fak levels in Ring1B-
depleted cells (Figure 4A) and Tgfβ-induced Y861-Fak 
phosphorylation is impaired in these cells (Suppl. Figure 
2). 
Fak tyrosine phosphorylation occurs at six or more 
sites in vivo and phosphorylation at the C-terminal Tyr 
861 and 925 creates binding sites for the src homology 
2 (SH2)-containing proteins, which are thus likely to 
participate in the regulation of downstream targets 
such as the Erk/MAP kinase cascade [32]. We therefore 
investigated Erk phosphorylation in control and Ring1B-
depleted cells. Tgfβ treatment for 24 hours results in 
depression to below basal levels of Erk phosphorylation 
in control cells, whereas Erk phosphorylation is barely 
affected by Tgfβ treatment in Ring1B depleted cells 
(Figure 4B). In contrast, both control and Ring1B 
depleted cells are sensitive to the strong activator of the 
Erk signaling pathway TPA (Suppl. Figure 3), suggesting 
that the observed differences in Erk regulation upon Tgfβ 
treatment are due to a defective Fak pathway upstream of 
Erk in Ring1B depleted cells.    
Next we determined whether Ring1B modulation 
impinge on Fak subcellular localization. Whereas some 
Figure 3: Ectopic Ring1B is able to induce Fak 
expression and cell migration. A. Ectopically expressed 
Ring1B enhances Fak expression, as determined by western 
blot. Lamin B, loading control. Numbers at the bottom of each 
western blot lane represent protein band intensities normalized to 
Lamin B and relative to control cells, as described in “Methods”. 
B. Focal contact formation in Ring1B overexpressing NMuMG 
cells, determined by immunofluorescence to detect Fak. Bars, 
10 μm.  C. Ectopic Ring1B expression results in NMuMG cell 
migration, determined by scratch assays. Graph shows data 
(mean ± SD) from a wound healing assay of NMuMG cells 
transfected with empty or Ring1B expression vectors. Bars, 2 
mM. Experiment was performed in triplicate and repeated three 
times with similar results. **, P < 0.005.
Figure 4: Endogenous Ring1B is required to 
sustain steady state levels of Fak, modulate Erk 
phosphorylation and to allow Fak recruitment to focal 
adhesions upon Tgfβ treatment in mammary cancer 
cell lines.  A. Cells were oligofected with mock or Ring1B 
siRNA and 24 hours later treated with 2 ng/ml Tgfβ. 48 h after 
transfection, protein and mRNA levels of Fak were determined 
by western blot and qRT-PCR, respectively. Effectiveness of 
Ring1B downregulation was confirmed by western blot (upper 
panel) and qRT-PCR (Supplementary Figure 1). α-Tubulin and 
Lamin B, loading controls. *, P < 0.05; **, P < 0.005. B. Erk 
phosphorylation in Ring1B-depleted cells upon Tgfβ treatment. 
MCF7 and MDA-MB-231 cells were treated as above and 48 
hours later p-Erk 1/2 levels were determined by western blot. 
Erk 2, loading control. C. Subcellular localization of Fak in 
Ring1B depleted cells upon Tgfβ treatment, monitored by 
immunofluorescence. Arrows indicate focal adhesions. Bar, 75 
μm.
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discrete punctate focal complexes at the cell periphery 
and a diffuse staining in the cytoplasm can be observed in 
basal conditions, Tgfβ treatment induces Fak translocation 
to newly formed focal adhesions (Figure 4C). In contrast, 
Ring1B depletion prevents Fak accumulation at focal 
adhesion complexes in basal and Tgfβ conditions (Figure 
4C). 
Fak regulates steady-state adhesive forces by 
modulating Vinculin recruitment to focal adhesions [34]. 
Therefore we examined Vinculin localization in MDA-
MB-231 cells stably depleted of Ring1B (shRing1B) 
(Figure 5A, upper panel). Immunofluorescence analysis 
of control (shMock) and shRing1B MDA-MB-231 cells 
revealed that the number of focal adhesions is significant 
reduced in shRing1B cells when compared to shMock 
MDA-MB-231 cells. Furthermore, Tgfβ treatment 
significantly increases the number of Vinculin-containg 
focal adhesions in shMock cells, but does not affect the 
number of Vinculin focal adhesions in shRing1B cells 
(Figure 5A).
Since Vinculin is an F-actin binding protein and this 
Figure 5: Endogenous Ring1B is required to allow 
Tgfβ-induced focal adhesion formation and phenotypic 
changes in mammary cancer cell lines.  A. Upper panel, 
efficiency of stable Ring1B knockdown (short hairpin, sh) in 
MDA-MB-231 cells determined by western blot. Lower panel, 
Vinculin inmunostaining in shMock and shRing1B MDA-
MB-231 cells untreated or treated with 2 ng/ml Tgfβ. Bars, 20 
µm. On the right, quantification of Vinculin foci, performed with 
a 40× objective. For quantification, more than 150 cells were 
scored from at least eight random fields in each group and data 
are mean ± SD. ***, P < 0.001; n. s., non-significant. B. Cells 
were oligofected with mock or Ring1B siRNA and treated with 
2 ng/ml Tgfβ. Fourty eight hours later cells were stained with 
Rhodamine-Phalloidin, which binds specifically to F-actins 
to visualize stress fibers, actin filaments and focal contacts at 
stress fiber termini. Note that Tgfβ causes loss of intercellular 
adhesions and projection of cytoplasmic protrusions from the 
cellular body in control cells. In contrast, Ring1B-depleted cells 
are defective in forming these Tgfβ-induced extensions and 
MCF7 cells are also defective in losing cell-to-cell contacts in 
response to Tgfβ treatment. Bar, 50 μm.
Figure 6: Ring1B is required for cell migration and 
invasion. A. Wound healing assays of MCF7 cells oligofected 
with mock or Ring1B siRNA. Pictures were taken after 24 and 48 
hours (left panel) and the area of the scratch remaining unfilled 
was quantified (right panel). Bars, 2 mM. Graph displays mean 
± SD of three independent experiments performed in triplicate. 
*, P<0.05. B. Defective migration and invasion abilities of 
Ring1B-depleted MDA-MB-231 cells, analyzed by transwell 
assays. shRing1B migration and invasion are expressed as fold 
versus controls, shown as mean ± SD from two independent 
experiments performed in triplicate. ***, P < 0.001 C. Section of 
the colonies formed in Matrigel from siMock or siRing1B MDA-
MB-231 cells, analyzed by Phalloidin staining (in red). DAPI 
was used for labeling cell nuclei (in blue). Bars, 50 and 25 μm 
(left and right pictures, respectively). D. Hematoxylin and Eosin 
staining of representative tumors from nude mice injected with 
control or Ring1B-depleted MDA-MB-231 cells (1x106) into 
the mammary fat pad and sacrificed when their tumors reached 
0.8 cm3. Bars, 100 μM. E. Immunohistochemistry detection of 
S100A4 in representative MDA-MB-231 orthotopic tumors. 
Bars, 100 μM. x20, original magnification. Right pictures, 
higher magnifications of the indicated fields.
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interaction is critical to coordinate F-actin organization 
and focal adhesion dynamics at the leading edge [35], 
we next analyzed the role of Ring1B in Tgfβ induced-
morphologic changes by cytoskeletal F-actin labeling 
with Rhodamine-Phalloidin. No obvious or very subtle 
changes in cell morphology can be observed in Ring1B-
depleted cells in basal conditions (in the absence of 
Tgfβ) when compared to control cells, whereas Ring1B 
depletion prevents Tgfβ−dependent stress fiber and focal 
contact formation (Figure 5B). These data indicate that 
endogenous Ring1B is required to sustain steady state 
Fak levels required for activation upon Tgfβ stimulus in 
mammary tumoral cells.
Ring1B is required for cell migration and invasion 
of breast cancer cells
We next assessed whether Ring1B deficiency 
functionally affects the mobility abilities of breast 
tumoral cells in vitro. Cell migration analysis performed 
by a scratch in the monolayer of confluent cultures 
showed that MCF7 control cells extensively migrate into 
the wounded area, whereas cell intrinsic migration is 
impaired in Ring1B-depleted cells (Figure 6A). We also 
examined the migratory and invasive abilities of shMock 
and shRing1B MDA-MB-231 cells by using transwell 
migration and invasion assays. As Figure 6B shows, 
Ring1B depletion significantly blocked cell migration 
and invasion in these cells. Next we tested whether this 
effect could be extended to other breast cancer cell lines. 
Indeed, MDA-MB-468, SUM159, BT549, SUM149 
and SUM1315 cells transiently transfected with Ring1B 
siRNA display impaired abilities to migrate and to invade 
through basement membrane extract when compared 
to siMock control cells (Suppl. Figure 4). Furthermore, 
in three dimensional (3D) cultures, parental MDA-
MB-231 cells invade the extracellular Matrigel matrix 
and F-actin accumulates mainly at the cell rear, whereas 
Ring1B-depleted MDA-MB-231 cells form acini-like 
spheroids with a hollow lumen (Figure 6C). Thus, Ring1B 
downregulation impairs the ability of mammary epithelial 
tumor cells to migrate and invade in vitro. 
Next, we sought to determine whether Ring1B 
could be required for in vivo invasion by orthotopically 
injecting MDA-MB-231 cells stably depleted of 
Ring1B into mammary fat pads of female mice. Ring1B 
knockdown causes tumors that are histologically distinct 
from those originated by shMock MDA-MB-231 cells: 
whereas control tumors are poorly differentiated and 
clearly invade the surrounding adipose tissue, shRing1B 
tumors display polygonal cells that are unable to invade 
the adipose component (Figure 6D). To better characterize 
these tumors we performed immunohistochemistry 
to detect S100A4. Interestingly, three out of the five 
analyzed tumors formed by control MDA-MB-231 cells 
display intensity levels above 2 and mainly nuclear 
S100A4 staining, whereas S100A4 expression in all the 
tumors from Ring1B-depleted cells corresponds to an 
intensity of 1 and the staining is diffusely distributed 
(Figure 6E). Since Ring1B-depleted and control MDA-
MB-231 cells proliferate in culture to a similar extent and 
form subcutaneous tumors of similar size (unpublished 
observations), these results indicate that endogenous 
Ring1B expression is necessary for regional spreading of 
Figure 7: Identification of ∆Np63 as a molecular target 
involved in Ring1B-sustained Fak expression. A. 
Analysis of ∆Np63 expression in cells depleted from Ring1B, 
detected by western blot analysis of nuclear extracts and qRT-
PCR. *, P < 0.05. B. Cells depleted from Ring1B displayed 
an impoverishment of ∆Np63 promoter ubiquitination, as 
determined by chromatin immunoprecipitation (ChIP) of MCF7 
cells transfected with GFP-tagged ubiquitin and oligofected with 
mock or Ring1B siRNA. Graph displays percentage of Ub-GFP 
recruitment to ∆Np63 promoter relative to input values and 
expressed as mean ± SD of two independent experiments. C. 
Ectopic ∆Np63 represses Fak expresion in transiently transfected 
MCF7 cells, as shown by western blot analysis and qRT-PCR. 
D. Effect of Ring1B dowregulation on Fak expression in cells 
oligofected with p63 siRNA, detected by western blot. E. Tgfβ 
represses ∆Np63 expression in MCF7 and MDA-MB-231 cells 
and induces ubiquitination of endogenous ∆Np63 promoter in 
MCF7 cells transiently transfected with GFP-tagged ubiquitin, 
as detected by ChIP. Graph displays percentage of GFP-ubiquitin 
recruitment to ∆Np63 promoter normalized to input values and 
expressed as mean ± SD of three replicate samples from one 
representative experiment out of two.
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the tumoral cells.
Ring1B sustains Fak steady state levels by 
repressing p63 
Next we attempted to identify the mechanism 
underlying the regulation of Fak expression by Ring1B 
in breast cancer cells. Ring1B is a histone ubiquitin-ligase 
mainly associated with gene silencing [36]. Therefore, 
the molecular mechanism involved in Ring1B-sustained 
steady state levels of Fak would likely be indirect via 
repression of a Fak inhibitor. According to this hypothesis 
Ring1B knockdown should result in the enhanced 
expression of a Fak repressor. Fak promoter contains p53 
binding sites [30] and wild type, but not mutant, p53 binds 
to Fak promoter in vivo and inhibits Fak expression in 
cancer cells [37]. Therefore, we tested the possibility that 
Ring1B downregulation releases p53 expression, resulting 
in Fak repression. However, Ring1B depletion does not 
affect p53 protein levels neither in the p53-wild type 
MCF7 cells nor in the p53-mutant MDA-MB-231 cells 
(data not shown). A closely p53-related protein is p63, 
which can be transcribed from two different promoters, 
one that retains and another that lacks the transactivation 
domain (TA and ∆N, respectively) [38]. Since p63 DNA-
binding domain is 60% identical to that of p53 and is able 
to interact with the consensus p53-responsive sequences 
[38,39], we checked whether p63 expression is affected 
by Ring1B depletion. Ring1B downregulation in MCF7 
and MDA-MB-231 cells results in an enhancement 
of ∆Np63 expression, the isoform predominantly 
expressed in epithelial cells (Figure 7A). In addition, 
since Ring1B monoubiquitinates H2A, we also tested 
whether ubiquitination of ∆Np63 promoter is sensitive 
to Ring1B depletion. Indeed, GFP-ubiquitin-tagged cells 
transfected with Ring1B siRNA display reduced levels 
of GFP-ubiquitin at the ∆Np63 promoter, suggesting 
that this promoter is directly and actively repressed by 
Ring1B-mediated histone ubiquitination (Figure 7B). To 
investigate ∆Np63 ability to modulate Fak expression, 
MCF7 cell were transiently transfected with ∆Np63 
expression vector. Indeed, ∆Np63 overexpression results 
in a decrease in Fak expression (Figure 7C), suggesting 
that release of ∆Np63 expression upon Ring1B depletion 
could be responsible for the observed Fak downregulation. 
To formally test this possibility we checked whether 
Ring1B knockdown affects Fak expression in p63 
deficient cells. To this end, MCF7 and MDA-MB-231 
cells were oligofected with p63 siRNA and the efficiency 
of the knockdown was evaluated by western blot and qRT-
PCR (Suppl. Figure 5). In p63-deficient cells, Ring1B 
depletion does not result in diminished Fak levels (Figure 
7D), suggesting that release of p63 expression is required 
to mediate Fak repression upon Ring1B downregulation. 
Since we consistently observed that Tgfβ treatment 
moderately induces Ring1B expression, we wondered 
whether the cytokine could reinforce Ring1B-mediated 
∆Np63 repression. Indeed, Tgfβ treated cells display lower 
levels of ∆Np63 (Figure 7E) and enhanced levels of GFP-
ubiquitin at ∆Np63 promoter (Figure 7F), pointing to a 
direct role of Ring1B in Tgfβ-mediated ∆Np63 regulation. 
DISCUSSION
Metastasis is the main cause of death in cancer 
patients and is widely considered a multistep process 
initiated when cells originating from the primary tumor 
undergo several morphological changes, acquiring the 
ability to spread to distant organs. We had previously 
shown that Ring1B expression is overexpressed in 
high-grade pancreatic intraepithelial neoplasia and in 
pancreatic ductal adenocarcinoma [24]. Supporting 
Ring1B involvement in cancer progression, its strongest 
expression is found in those tumoral cells with nuclear 
expression of the metastasis-promoting protein S100A4 
that invade the adipose tissue both in human IDC as well 
as in mammary gland xenografts. Importantly, in this 
experimental model, Ring1B depleted MDA-MB-231 
cells fail to invade the surrounding mammary fat pad 
and display reduced S100A4 nuclear staining. These data 
suggest that endogenous Ring1B levels in tumoral cells 
of the IDC invading front could be regulated by growth 
factors or cytokines produced by the tumor or the tumoral 
stroma, such as Tgfβ.
Ring1B displays an overlapping expression pattern 
with Fak in IDC tumors and ectopic Ring1B in cell lines in 
culture results in Fak induction. Orthotopic and transgenic 
mouse models of breast cancer revealed that Fak signaling 
is essential during the initial steps of metastasis formation 
for the transition of premalignant hyperplasia to carcinoma 
and the subsequent metastases [29,40]. Furthermore, Fak 
protein has been shown to be elevated in tumour tissues 
[41] and the underlying genetic mechanisms include 
copy number gains, amplification and isochromosome 
formation involving the FAK locus [42]. Our results 
indicate that Ring1B is necessary to sustain Fak basal 
levels in breast tumor cell lines, for proper cell migration 
and invasion and for Tgfβ−dependent stress fiber and focal 
contact formation. Accordingly, Ring1B was shown to be 
essential in maintaining an undifferentiated state in stem 
cells by affecting ECM-related pathways that are known 
to be involved in the regulation of Fak phosphorylation 
as well [36]. Recent data demonstrate Ring1B ability 
to function as E3-ligase in the ubiquitination of 
proteins other than histones [43,44]. Therefore, Ring1B 
requirement for Fak activation could rely not only on 
mechanisms of transcriptional repression but can also be 
due to postranslational modifications of proteins involved 
in Tgfβ-signal transduction. Further efforts will be 
required to characterize other targets of Ring1B-mediated 
ubiquitination and whether any of them can have an 
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impact on Fak function. 
Ring1B depletion resulted in a decrease in Fak 
expression concomitant with an increase in ∆Np63 
levels and to a drop in the ubiquitination degree of 
∆Np63 promoter. Ectopic ∆Np63 is able to repress 
Fak expression, possibly by transcriptional and 
posttranscriptional mechanisms. Indeed, it has been 
reported that ∆Np63 modulates the expression of Hsp70, a 
chaperone that prevents caspase 3-mediated proteolysis of 
Fak [45]. In addition, Hsp70 overexpression is associated 
with metastasis and with short-term disease free survival 
metastasis and poor prognosis in breast cancer [46]. 
Therefore, Ring1B repression of ∆Np63 could be critical 
for the maintenance of Fak expression and activity in 
breast tumoral cells. 
CONCLUSIONS
The PcG protein Ring1B is overexpressed in 
invasive ductal breast carcinoma and its expression 
pattern in these tumors is coincidental with Fak expression 
pattern. Endogenous Ring1B sustains Fak steady state 
levels in breast cancer cells and is required for in vitro and 
in vivo migration and invasion. Therefore we propose that 
Ring1B should be considered as a new molecular marker 
for tumoral progression and as a putative therapeutic 
target.
METHODS
Human breast cancer samples
Ten human breast cancer tissues from the Pathology 
Department (Hospital del Mar) were evaluated by 
an expert pathologist (JMC) to classify the lesions. 
Procedures were approved by the Ethical Committee for 
Clinical Research of our institution (Institut Municipal 
d´Assistència Sanitària, Protocol # 2008/3275/I), waiving 
the requirement for informed consent for the study. A 
commercially available breast cancer tissue array (Biomax 
Inc., Rockville, MD, USA; cat. No. BR243f) including 
6 cases of breast invasive ductal carcinoma was also 
analyzed by immunohistochemistry.
Immunohistochemistry
Immunohistochemical analyses were performed 
using 5 μm sections of formalin-fixed, paraffin-embedded 
tissue blocks. Antigen retrieval was performed in 10 
mM citrate (pH 6) for 15 min in a pressure cooker. The 
slides were then incubated with primary antibodies for 
12 hours. After washing, the Envision+ System-HRP 
antibody reagent was applied (Dako, Glostrup, Denmark). 
Reactions were developed using diaminobenzidine (DAB) 
as chromogenic substrate. Sections were counterstained 
with hematoxylin, dehydrated and mounted. For 
sequential horseradish peroxidase/alkaline phosphatase 
(HRP/AP) immunoenzymatic double staining analysis 
of Ring1B and Fak, sections were first stained with 
primary anti-Ring1B, followed by Envision+ System-HRP 
antibody. Subsequently slides were washed extensively 
and incubated with anti-Fak primary antibody followed 
by incubation with AP-conjugated secondary antibody. 
Finally, HRP activity was developed as above and AP 
detection was performed by incubation with K1395 
Fast Red reagent (Dako, Glostrup, Denmark). Ring1B, 
Bmi1 and Fak antibodies were purchased from Millipore 
(Billerica, MA, USA) and S100A4 antibody was from 
Abcam (Cambridge, MA, USA). AP-conjugated secondary 
antibody was purchased from Dako (Glostrup, Denmark).
Immunohistochemical staining was scored by two 
observers (AB and IHM). The intensity (0, 1, 2, 3) of the 
immunostaining was evaluated and scored as follows: 0, 
negative or trace amounts; 1, low staining; 2, medium 
staining; 3, strong staining. Results are expressed as 
mean [confidence interval] and statistical analysis was 
performed with the Spearman´s rho.
Cell culture conditions
Cells were grown in DMEM or DMEM:F12 (Gibco, 
Life Technologies, Paisley, UK) in standard conditions. To 
perform Tgfβ treatments, cells were treated with 2 ng/ml 
Tgfβ (Peprotech, Rocky Hill, NJ, USA) for 24 hours. TPA 
(12-O-tetradecanoylphorbol-13-acetate) was purchased 
from Sigma (St. Louis, MO, USA) and cells were treated 
with 200 nM TPA for 24 hours or 15 minutes.
Oligofection, transfection and retroviral infection
Oligofection has been performed as described 
earlier [24]. To generate retroviral stocks, Phoenix cells 
were transfected with Fugene (Roche, Indianapolis, IN, 
USA). For stable expression of Ring1B short hairpin 
RNA (shRNA), cells were transduced with retroviral 
supernatants in the presence of Polybrene (4 μg/ml; 
Sigma, St. Louis, MO, USA) and selected with 2 μg/ml 
Puromycin (Sigma, St. Louis, MO, USA). For transient 
expression of GFP-ubiquitin, ∆Np63 or Ring1B cells 
were transfected with Lipofectamine 2000 (Invitrogen, 
Life Technologies, Paisley, UK). Expression vector for 
Ring1B was generated by using standard PCR methods 
and verified by sequencing. GFP-ubiquitin expression 
vector was obtained from Addgene (plasmid 11928)
[47]. ∆Np63 expression vector was a generous gift from 
Dr. Caron de Fromentel (INSERM U590, Lyon, France). 
Retroviral constructs carrying shRNA sequences with 
Puromycin resistance were essentially made as previously 
described [48]. Mock, Ring1B and p63 siRNA sequences 
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are available upon request. 
Protein extraction, western blot and 
immunofluorescence
These protocols have been performed following 
standard techniques. Ring1B, Fak and p63 antibodies were 
purchased from Millipore (Billerica, MA, USA). pY861-
Fak antibody was from Biosource International (Life 
Technologies, Paisley, UK). Anti-activated MAP kinase 
(diphosphorylated Erk 1/2) was from Sigma (St. Louis, 
MO, USA) and Erk 2 (C-14) antibody was purchased from 
Santa Cruz Biotechnology (Heidelberg, Germany). Lamin 
B1 antibody was from Abcam (Cambridge, MA, USA) 
and Vinculin and α-Tubulin antibodies from Sigma (St. 
Louis, MO, USA). Fluorescent secondary antibodies were 
obtained from Invitrogen (Life Technologies, Paisley, UK) 
and Jackson ImmunoResearch Laboratories (West Grove, 
PA, USA). Rhodamine-Phalloidin was from Sigma (St. 
Louis, MO, USA). For focal contact counting, the cells 
were labeled with anti-Vinculin antibody and the Vinculin-
positive patches were manually counted.
Western blot quantification was performed using 
Image J densitometry software. The intensity of individual 
bands was normalized to Lamin B or α-Tubulin signal, as 
a measure of protein relative abundance in the different 
samples and referred to control conditions.
RNA isolation and qRT-PCR
RNA was isolated with Genelute Total Mammalian 
RNA Kit (Sigma, St. Louis, MO, USA) and cDNA 
was obtained by using Transcriptor First Strand cDNA 
Synthesis Kit (Roche, Indianapolis, IN, USA). qRT-
PCR assays were performed using SYBR Green PCR 
master mix (Applied Biosystems, Life Technologies, 
Paisley, UK)). For normalization purposes, we run 
simultaneously qRT-PCR with primers for Gapdh. 
The ABI PRISM 7900HT cycler’s software calculated 
a threshold cycle number (Ct) at which each PCR 
amplification reached a significant threshold level. Figures 
present the amount of target mRNA/Gapdh mRNA 
relative copies ratio. Primers used for qRT-PCR were: 
Ring1B (5’-CAGACAAACGGAACTCAACCATT-3’; 
5’-CTGTTATTGCCTCCTGAGGTGTT-3’), Fak 
(5’-GCAGTCATTTATCATCAGACCTCAGA-3’; 
5’-GCCTTGCTTTTCGCTGTTG-3’); p63 
(5´-CTTGCCCAGGAAGAGACAGG-3´; 
5´-CATAAGTCTCACGGCCCCTC-3´); Gapdh 
(5’-AGTCAGCCGCATCTTCTTTTG-3’; 
5’-AAATCCGTTGACTCCGACCTT-3’).
Chromatin immunoprecipitation assays (ChIP)
GFP-ubiquitin tagged cells were cross-linked with 
1 % formaldehyde for 10 min and lysed in buffer IP1 (10 
mM Hepes-KOH pH 7.5, 10 mM NaCl, 3 mM CaCl
2
, 
0.25 M sucrose, 1 mM DTT, 1 mM PMSF).  After 30 min 
on ice, nuclei were collected by centrifugation at 3000 g 
for 10 min. The pellet was lysed in IP2 buffer (50 mM 
Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonication 10 
times at 40 % 10 sec (Branson). Immunoprecipitation 
was carried out with anti-GFP antibody (Clontech, 
Mountain View, CA, USA) or irrelevant immunoglobulin 
G (Sigma, St. Louis, MO, USA) in IP buffer (16.7 
mM Tris pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 1.1 
% Triton X-100, 0.01 % SDS). Samples were then 
processed as indicated in EZ ChIP™ Kit (Upstate, Cell 
Signaling Technology, Danvers, MA, USA). DNA 
was purified using GFX PCR DNA purification kit 
(Amersham, GE Healthcare Europe GmbH, Freiburg 
Germany). Promoter regions were detected by qPCR 
with SYBR Green PCR master mix (Applied Biosystems, 
Life Technologies, Paisley, UK). ChIP results were 
quantified relative to the input amount. Chromatin 
immunoprecipitation primers for human ∆Np63 
promoter were 5’-GGTTGGCAAAATCCTGGA-3’; 
5’-TCACTAAATTGAGTCTGGGCATT-3’.
Wound healing assay, transwell migration and 
invasion, 3D cultures and xenograft assays
Cells previously oligofected or transfected were 
seeded in standard conditions. 24 h later they were 
incubated with 10 μg/ml Mitomycin C (Sigma, St. 
Louis, MO, USA) for 1 h and confluent monolayers 
were scratched with a plastic pipette tip. Healing was 
measured at 0, 24 and 48 hours by using Image J software 
and expressed as a percentage of the area of the scratch 
remaining unfilled. 
Cell migration assays carried out in transwell 
chambers were performed as follows: cells were harvested 
with trypsin, washed with PBS and resuspended in serum-
free DMEM. Cells were placed in the upper compartment 
of a Transwell 96 well permeable supports (1x105 cells 
in 100 μl / well). The lower compartment was filled with 
DMEM supplemented with 10 % fetal bovine serum 
(FBS). The two compartments of the chambers were 
separated by a 8.0 μm pore size PET (polyester) membrane 
(Corning Costar, Acton, MA). Chambers were incubated 
at 37 °C in 5% CO
2
 for 24 h. At the end of the incubation 
period, cells remaining on the upper surface were 
mechanically removed and cells on the lower chamber 
were incubated 4 h with hexosaminidase substate [49]. 
Thereafter, developer solution was added to each well and 
absorbance at 410 nm was recorded with a fluorescent 
reader Infinite M200 (TECAN) [49]. For cell invasion 
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assays, PET membranes of the Transwell 96 permeable 
supports were coated with Basement Membrane Extract 
(Cultrex, AbBcn, Barcelona, Spain) and cells were 
processed as above. Assays were performed in triplicate 
and repeated two times.
3D cultures were performed as described previously 
[50]. In brief, 3x103 MDA-MB-231 oligofected cells were 
seeded onto Matrigel beds (BD Bioscience, Franklin 
Lakes, NJ, USA) in 8-well culture slides (BD Bioscience, 
Franklin Lakes, NJ, USA) and maintained in growth 
medium supplemented with 2 % Matrigel. Change of 
medium was performed every 48 hours for 12 days with 
additional oligofections at days 4 and 8 to maintain the 
knockdown. Cells were fixed on 4 % formaldehyde at day 
12 and stained with Texas Red-X Phalloidin (Invitrogen 
Life Technologies, Paisley, UK). Images were taken using 
a Leica TCS SP5 DMI microscope (Barcelona, Spain).
Orthotopic xenograft assays were performed as 
previously described [51]. Briefly, MDA-MB-231 cells 
were injected (1x106 in 0.05 mL serum-free growth 
medium) into the mammary fat pads of female athymic 
Nude mice aged 8 weeks (Charles River, Barcelona, 
Spain). Tumor growth was measured every 2 days and 
when they reached a size of 0.8 cm3, they were surgically 
excised. A minimum of 10 tumors from each condition 
were generated and, at least 4 different tumors derived 
from each condition were analyzed. Mice were used in 
accordance with institutional guidelines approved by the 
Use Committee for Animal Care.
Statistical Analysis
Each experiment was performed in triplicate at 
least three times unless otherwise indicated. Statistical 
analysis was performed with Student’s t-test. P < 0.05 was 
considered significant.
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